Regulation of angiogenesis by Th1- and Th2-type cytokines

被引:44
作者
Naldini, A [1 ]
Pucci, A [1 ]
Bernini, C [1 ]
Carraro, F [1 ]
机构
[1] Univ Siena, Dept Physiol, I-53100 Siena, Italy
关键词
angiogenesis; inflammation; immune response; cytokine; tumour; T lymphocyte;
D O I
10.2174/1381612033391423
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis is a complex process, where several cell types and mediators interact to establish a specific microenvironment suitable for the formation of new capillaries from pre-existing vessels. Such biological processes occur in several physiological conditions, such as embryo development and wound healing, as well as in pathological conditions, including tumours and diabetic retinopathy. T lymphocytes, neutrophils and monocytes fully participate in the angiogenic process by secreting cytokines that may control endothelial cell (EC) proliferation, their survival and apoptosis, as well as their migration and activation. Angiogenesis is the result of a net balance between the activities exerted by positive and negative regulators. This balance is conceptually very similar to that of the Th1/Th2 cells that modulate an appropriate and specific immune response. Th1 or Th2 cytokines may control angiogenesis directly, by acting on cell growth and differentiation, indirectly by inducing the release of other cytokines in the microenvironment, and by modulating the expression of specific receptors, involved in the control of angiogenic processes, such as EC proliferation and migration. In this review we will mainly discuss the role of Th1- and Th2-type cytokines in the angiogenic process, emphasizing the complexity of the cytokine and leukocyte/EC network, and highlighting the care that needs to be taken when designing new therapeutic interventions involving Th1 and Th2 cytokines.
引用
收藏
页码:511 / 519
页数:9
相关论文
共 92 条
[1]   Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells [J].
Arendt, BK ;
Velazquez-Dones, A ;
Tschumper, RC ;
Howell, KG ;
Ansell, SM ;
Witzig, TE ;
Jelinek, DF .
LEUKEMIA, 2002, 16 (10) :2142-2147
[2]   The IFN gamma receptor: A paradigm for cytokine receptor signaling [J].
Bach, EA ;
Aguet, M ;
Schreiber, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :563-&
[3]   IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ [J].
Beatty, GL ;
Paterson, Y .
JOURNAL OF IMMUNOLOGY, 2001, 166 (04) :2276-2282
[4]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[5]  
Cavallo F, 2001, CANCER RES, V61, P3518
[6]   Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10 [J].
Cervenak, L ;
Morbidelli, L ;
Donati, D ;
Donnini, S ;
Kambayashi, T ;
Wilson, JL ;
Axelson, H ;
Castaños-Velez, E ;
Ljunggren, HG ;
Malefyt, RD ;
Granger, HJ ;
Ziche, M ;
Bejarano, MT .
BLOOD, 2000, 96 (07) :2568-2573
[7]   Interleukin 6 induces the expression of vascular endothelial growth factor [J].
Cohen, T ;
Nahari, D ;
Cerem, LW ;
Neufeld, G ;
Levi, BZ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) :736-741
[8]   Interleukin-12 in anti-tumor immunity and immunotherapy [J].
Colombo, MP ;
Trinchieri, G .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :155-168
[9]  
DAEIPOUR M, 1993, J IMMUNOL, V150, P4743
[10]   Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma [J].
Dankbar, B ;
Padró, T ;
Leo, R ;
Feldmann, B ;
Kropff, M ;
Mesters, RM ;
Serve, H ;
Berdel, WE ;
Kienast, J .
BLOOD, 2000, 95 (08) :2630-2636